Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters

The International Transporter, 2010, Membrane transporters in drug development, Nat Rev Drug Discov, 9, 215, 10.1038/nrd3028 Yoshida, 2013, Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms, Annu Rev Pharmacol Toxicol, 53, 581, 10.1146/annurev-pharmtox-011112-140309 Maeda, 2015, Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs, Biol Pharm Bull, 38, 155, 10.1248/bpb.b14-00767 Talavera Pons, 2017, Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C, Br J Clin Pharmacol, 83, 269, 10.1111/bcp.13095 Niemi, 2011, Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake, Pharmacol Rev, 63, 157, 10.1124/pr.110.002857 Shitara, 2013, Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption, Biopharm Drug Dispos, 34, 45, 10.1002/bdd.1823 Iwatsubo, 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data, Pharmacol Ther, 73, 147, 10.1016/S0163-7258(96)00184-2 Obach, 1999, Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes, Drug Metab Dispos, 27, 1350 Watanabe, 2010, Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans, Drug Metab Dispos, 38, 215, 10.1124/dmd.109.030254 Izumi, 2017, Comparison of the predictability of human hepatic clearance for organic anion transporting polypeptide substrate drugs between different in vitro-in vivo extrapolation approaches, J Pharm Sci, 106, 2678, 10.1016/j.xphs.2017.02.012 Liu, 2005, The roles of transporters and enzymes in hepatic drug processing, Drug Metab Dispos, 33, 1, 10.1124/dmd.104.001149 Kusuhara, 2009, In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney, Drug Metab Pharmacokinet, 24, 37, 10.2133/dmpk.24.37 Shitara, 2006, Transporters as a determinant of drug clearance and tissue distribution, Eur J Pharm Sci, 27, 425, 10.1016/j.ejps.2005.12.003 Link, 2008, SLCO1B1 variants and statin-induced myopathy--a genomewide study, N Engl J Med, 359, 789, 10.1056/NEJMoa0801936 Hirano, 2004, Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans, J Pharmacol Exp Ther, 311, 139, 10.1124/jpet.104.068056 Vildhede, 2014, Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions, Drug Metab Dispos, 42, 1210, 10.1124/dmd.113.056309 Bi, 2019, Quantitative contribution of six major transporters to the hepatic uptake of drugs: "SLC-Phenotyping" using primary human hepatocytes, J Pharmacol Exp Ther, 370, 72, 10.1124/jpet.119.257600 Izumi, 2013, Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17beta-glucuronide, estrone-3-sulfate, and sulfobromophthalein, Drug Metab Dispos, 41, 1859, 10.1124/dmd.113.052290 Amundsen, 2010, Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin, Drug Metab Dispos, 38, 1499, 10.1124/dmd.110.032268 Chu, 2013, Species differences in drug transporters and implications for translating preclinical findings to humans, Expert Opin Drug Metabol Toxicol, 9, 237, 10.1517/17425255.2013.741589 Liao, 2019, Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans, Xenobiotica, 49, 852, 10.1080/00498254.2018.1512017 van de Steeg, 2010, Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs, J Clin Investig, 120, 2942, 10.1172/JCI42168 Imaoka, 2013, Integrated approach of in vivo and in vitro evaluation of the involvement of hepatic uptake organic anion transporters in the drug disposition in rats using rifampicin as an inhibitor, Drug Metab Dispos, 41, 1442, 10.1124/dmd.113.051052 Kimoto, 2017, Hepatobiliary clearance prediction: species scaling from monkey, dog, and rat, and in vitro-in vivo extrapolation of sandwich-cultured human hepatocytes using 17 drugs, J Pharm Sci, 106, 2795, 10.1016/j.xphs.2017.04.043 Shitara, 2003, Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes, Drug Metab Pharmacokinet, 18, 33, 10.2133/dmpk.18.33 De Bruyn, 2011, Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes, Eur J Pharm Sci, 43, 297, 10.1016/j.ejps.2011.05.002 Badolo, 2011, Effect of cryopreservation on the activity of OATP1B1/3 and OCT1 in isolated human hepatocytes, Chem Biol Interact, 190, 165, 10.1016/j.cbi.2011.02.025 Kotani, 2012, Expression and transport function of drug uptake transporters in differentiated HepaRG cells, Mol Pharm, 9, 3434, 10.1021/mp300171p Schaefer, 2018, Quantitative expression of hepatobiliary transporters and functional uptake of substrates in hepatic two-dimensional sandwich cultures: a comparative evaluation of upcyte and primary human hepatocytes, Drug Metab Dispos, 46, 166, 10.1124/dmd.117.078238 McGinnity, 2004, Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance, Drug Metab Dispos, 32, 1247, 10.1124/dmd.104.000026 Umehara, 2007, Functional involvement of organic cation transporter 1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats, Xenobiotica, 37, 818, 10.1080/00498250701546012 Bow, 2008, Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes, Drug Metab Dispos, 36, 198, 10.1124/dmd.107.018200 Soars, 2007, Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo, Drug Metab Dispos, 35, 859, 10.1124/dmd.106.014464 Bi, 2006, Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport, Drug Metab Dispos, 34, 1658, 10.1124/dmd.105.009118 Swift, 2010, Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity, Drug Metab Rev, 42, 446, 10.3109/03602530903491881 Kotani, 2011, Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes, Drug Metab Dispos, 39, 1503, 10.1124/dmd.111.038968 Kimoto, 2012, Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes, Drug Metab Dispos, 40, 407, 10.1124/dmd.111.039297 Ulvestad, 2011, OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture, Biochem Pharmacol, 82, 1219, 10.1016/j.bcp.2011.07.076 Bi, 2017, Reliable rate measurements for active and passive hepatic uptake using plated human hepatocytes, AAPS J, 19, 787, 10.1208/s12248-017-0051-2 Kumar, 2019, A comparison of total and plasma membrane abundance of transporters in suspended, plated, sandwich-cultured human hepatocytes versus human liver tissue using quantitative targeted proteomics and cell surface biotinylation, Drug Metab Dispos, 47, 350, 10.1124/dmd.118.084988 Yoshikado, 2016, Quantitative analyses of hepatic OATP-mediated interactions between statins and inhibitors using PBPK modeling with a parameter optimization method, Clin Pharmacol Ther, 100, 513, 10.1002/cpt.391 Konig, 1999, Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane, Hepatology, 29, 1156, 10.1002/hep.510290404 Rius, 2003, Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane, Hepatology, 38, 374, 10.1053/jhep.2003.50331 Ghosh, 2014, Toward a unified model of passive drug permeation II: the physiochemical determinants of unbound tissue distribution with applications to the design of hepatoselective glucokinase activators, Drug Metab Dispos, 42, 1599, 10.1124/dmd.114.058032 Fujino, 2018, Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake, Eur J Pharm Sci, 125, 181, 10.1016/j.ejps.2018.09.021 Kim, 2017, Quantitative analysis of complex drug-drug interactions between repaglinide and cyclosporin A/gemfibrozil using physiologically based pharmacokinetic models with in vitro transporter/enzyme inhibition data, J Pharm Sci, 106, 2715, 10.1016/j.xphs.2017.04.063 Varma, 2015, Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS), Pharm Res, 32, 3785, 10.1007/s11095-015-1749-4 Maeda, 2011, Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study, Clin Pharmacol Ther, 90, 575, 10.1038/clpt.2011.142 Yoshikado, 2017, A clinical cassette dosing study for evaluating the contribution of hepatic OATPs and CYP3A to drug-drug interactions, Pharm Res, 34, 1570, 10.1007/s11095-017-2168-5 Watanabe, 2011, Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments, Drug Metab Dispos, 39, 1031, 10.1124/dmd.110.036129 Bosgra, 2014, Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling, Eur J Pharm Sci, 65, 156, 10.1016/j.ejps.2014.09.007 Miyauchi, 2018, The phenomenon of albumin-mediated hepatic uptake of organic anion transport polypeptide substrates: prediction of the in vivo uptake clearance from the in vitro uptake by isolated hepatocytes using a facilitated-dissociation model, Drug Metab Dispos, 46, 259, 10.1124/dmd.117.077115 De Bruyn, 2018, Predicting human clearance of organic anion transporting polypeptide substrates using cynomolgus monkey: in vitro-in vivo scaling of hepatic uptake clearance, Drug Metab Dispos, 46, 989, 10.1124/dmd.118.081315 Matsunaga, 2019, Hepatic organic anion transporting polypeptide-mediated clearance in the beagle dog: assessing in vitro-in vivo relationships and applying cross-species empirical scaling factors to improve prediction of human clearance, Drug Metab Dispos, 47, 215, 10.1124/dmd.118.084194 Kim, 2019, Drug Metab Dispos, 47, 94, 10.1124/dmd.118.083733 Izumi, 2018, Relative activity factor (RAF)-Based scaling of uptake clearance mediated by organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 in human hepatocytes, Mol Pharm, 15, 2277, 10.1021/acs.molpharmaceut.8b00138 Lundquist, 2014, Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition, Drug Metab Dispos, 42, 448, 10.1124/dmd.113.054528 Mathialagan, 2017, Quantitative prediction of human renal clearance and drug-drug interactions of organic anion transporter substrates using in vitro transport data: a relative activity factor Approach, Drug Metab Dispos, 45, 409, 10.1124/dmd.116.074294 Billington, 2019, PET imaging of [(11) C]rosuvastatin hepatic concentrations and hepatobiliary transport in humans in the absence and presence of cyclosporine A, Clin Pharmacol Ther, 106, 1056, 10.1002/cpt.1506 Watanabe, 2009, Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans, J Pharmacol Exp Ther, 328, 652, 10.1124/jpet.108.146647 Menochet, 2012, Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes, Drug Metab Dispos, 40, 1744, 10.1124/dmd.112.046193 Jones, 2012, Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data, Drug Metab Dispos, 40, 1007, 10.1124/dmd.111.042994 Tournier, 2018, Imaging techniques to study drug transporter function in vivo, Pharmacol Ther, 189, 104, 10.1016/j.pharmthera.2018.04.006 Riccardi, 2019, A novel unified approach to predict human hepatic clearance for both enzyme- and transporter-mediated mechanisms using suspended human hepatocytes, Drug Metab Dispos, 47, 484, 10.1124/dmd.118.085639 Shitara, 2006, Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions, Pharmacol Ther, 112, 71, 10.1016/j.pharmthera.2006.03.003 Omar, 2002, FDA adverse event reports on statin-associated rhabdomyolysis, Ann Pharmacother, 36, 288, 10.1345/aph.1A289 2017 2012 2019 Li, 2014, Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved, Clin Pharmacokinet, 53, 659, 10.1007/s40262-014-0156-z Fukuchi, 2017, Analysis of nonlinear pharmacokinetics of a highly albumin-bound compound: contribution of albumin-mediated hepatic uptake mechanism, J Pharm Sci, 106, 2704, 10.1016/j.xphs.2017.04.052 Sato, 2018, Physiologically based pharmacokinetic modeling of bosentan identifies the saturable hepatic uptake as a major contributor to its nonlinear pharmacokinetics, Drug Metab Dispos, 46, 740, 10.1124/dmd.117.078972 Snoeys, 2016, Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: a PBPK-guided drug development approach, Clin Pharmacol Ther, 99, 224, 10.1002/cpt.206 Lutz, 2018, Cytochrome P450 3A induction predicts P-glycoprotein induction; Part 1: establishing induction relationships using ascending dose rifampin, Clin Pharmacol Ther, 104, 1182, 10.1002/cpt.1073 Kyrklund, 2004, Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects, Br J Clin Pharmacol, 57, 181, 10.1046/j.1365-2125.2003.01972.x Asaumi, 2019, Expanded physiologically-based pharmacokinetic model of rifampicin for predicting interactions with drugs and an endogenous biomarker via complex mechanisms including organic anion transporting polypeptide 1B induction, CPT Pharmacometrics Syst Pharmacol, 8, 845, 10.1002/psp4.12457 Maeda, 2006, Uptake of ursodeoxycholate and its conjugates by human hepatocytes: role of Na(+)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and oatp1B3 (OATP8), Mol Pharm, 3, 70, 10.1021/mp050063u Bi, 2013, Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin, Biopharm Drug Dispos, 34, 452, 10.1002/bdd.1861 Crespi, 1995, Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research, 179, 10.1016/S0065-2490(05)80006-1 Hasegawa, 2003, Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat, J Pharmacol Exp Ther, 305, 1087, 10.1124/jpet.102.046847 Yamashiro, 2006, Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans, Drug Metab Dispos, 34, 1247, 10.1124/dmd.105.008938 Kitamura, 2008, Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin, Drug Metab Dispos, 36, 2014, 10.1124/dmd.108.021410 Imamura, 2011, Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion, Clin Pharmacol Ther, 89, 81, 10.1038/clpt.2010.232 Nozaki, 2007, Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices, J Pharmacol Exp Ther, 321, 362, 10.1124/jpet.106.113076 Yamada, 2007, Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor, Drug Metab Dispos, 35, 2166, 10.1124/dmd.107.017459 Kunze, 2014, Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data, Drug Metab Dispos, 42, 1514, 10.1124/dmd.114.058412 Hirano, 2006, Drug-drug interaction between pitavastatin and various drugs via OATP1B1, Drug Metab Dispos, 34, 1229, 10.1124/dmd.106.009290 Zhang, 2019, Dissecting the contribution of OATP1B1 to hepatic uptake of statins using the OATP1B1 selective inhibitor estropipate, Mol Pharm, 16, 2342, 10.1021/acs.molpharmaceut.8b01226 Mitra, 2018, Prediction and quantification of hepatic transporter-mediated uptake of pitavastatin utilizing a combination of the relative activity factor Approach and mechanistic modeling, Drug Metab Dispos, 46, 953, 10.1124/dmd.118.080614 Williamson, 2013, Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA, Xenobiotica, 43, 920, 10.3109/00498254.2013.776194 Izumi, 2015, Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions, Drug Metab Dispos, 43, 235, 10.1124/dmd.114.059105 Shitara, 2017, Preincubation-dependent and long-lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug-drug interactions, Pharmacol Ther, 177, 67, 10.1016/j.pharmthera.2017.02.042 Noe, 2007, Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3, Drug Metab Dispos, 35, 1308, 10.1124/dmd.106.012930 Kenworthy, 1999, CYP3A4 drug interactions: correlation of 10 in vitro probe substrates, Br J Clin Pharmacol, 48, 716, 10.1046/j.1365-2125.1999.00073.x Obach, 2006, The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions, J Pharmacol Exp Ther, 316, 336, 10.1124/jpet.105.093229 Sharma, 2012, Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins, Eur J Pharm Sci, 47, 244, 10.1016/j.ejps.2012.04.003 Shitara, 2004, J Pharmacol Exp Ther, 311, 228, 10.1124/jpet.104.068536 Kindla, 2011, Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport, Drug Metab Dispos, 39, 1047, 10.1124/dmd.110.037622 Yamaguchi, 2006, Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3, J Lipid Res, 47, 1196, 10.1194/jlr.M500532-JLR200 Annaert, 2010, Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1, Xenobiotica, 40, 163, 10.3109/00498250903509375 de Waart, 2010, Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein, J Pharmacol Exp Ther, 334, 78, 10.1124/jpet.110.166991 Baldes, 2006, Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3), Eur J Pharm Biopharm, 62, 39, 10.1016/j.ejpb.2005.06.001 Gui, 2008, Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3, Eur J Pharmacol, 584, 57, 10.1016/j.ejphar.2008.01.042 Gui, 2010, Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3, Curr Chem Genom, 4, 1, 10.2174/1875397301004010001 De Bruyn, 2011, Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3, J Pharm Sci, 100, 5018, 10.1002/jps.22694 Bednarczyk, 2010, Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3, Anal Biochem, 405, 50, 10.1016/j.ab.2010.06.012 Izumi, 2016, Investigation of fluorescein derivatives as substrates of organic anion transporting polypeptide (OATP) 1B1 to develop sensitive fluorescence-based OATP1B1 inhibition assays, Mol Pharm, 13, 438, 10.1021/acs.molpharmaceut.5b00664 Zolk, 2009, Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2), Naunyn Schmiedeberg's Arch Pharmacol, 379, 337, 10.1007/s00210-008-0369-5 Belzer, 2013, Substrate-dependent ligand inhibition of the human organic cation transporter OCT2, J Pharmacol Exp Ther, 346, 300, 10.1124/jpet.113.203257 Lechner, 2016, Impact of experimental conditions on the evaluation of interactions between multidrug and toxin extrusion proteins and candidate drugs, Drug Metab Dispos, 44, 1381, 10.1124/dmd.115.068163 Shen, 2013, Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance, Drug Metab Dispos, 41, 2095, 10.1124/dmd.113.053215 Zhou, 2005, Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs, Clin Pharmacokinet, 44, 279, 10.2165/00003088-200544030-00005 Obach, 2007, Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions, Drug Metab Dispos, 35, 246, 10.1124/dmd.106.012633 Varma, 2012, Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions, Pharm Res, 29, 2860, 10.1007/s11095-012-0792-7 Furihata, 2014, Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides, Antimicrob Agents Chemother, 58, 4555, 10.1128/AAC.02724-14 Gertz, 2013, Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential, Pharm Res, 30, 761, 10.1007/s11095-012-0918-y Pahwa, 2017, Pretreatment with rifampicin and tyrosine kinase inhibitor dasatinib potentiates the inhibitory effects toward OATP1B1- and OATP1B3-mediated transport, J Pharm Sci, 106, 2123, 10.1016/j.xphs.2017.03.022 Farasyn, 2019, Preincubation with everolimus and sirolimus reduces organic anion-transporting polypeptide (OATP)1B1- and 1B3-mediated transport independently of mTOR kinase inhibition: implication in assessing OATP1B1- and OATP1B3-mediated drug-drug interactions, J Pharm Sci, 108, 3443, 10.1016/j.xphs.2019.04.019 Shitara, 2012, Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake, Drug Metab Pharmacokinet, 27, 368, 10.2133/dmpk.DMPK-11-RG-096 Shitara, 2009, Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats, Drug Metab Dispos, 37, 1172, 10.1124/dmd.108.025544 Taguchi, 2016, Characterization of long-lasting oatp inhibition by typical inhibitor cyclosporine A and in vitro-in vivo discrepancy in its drug interaction potential in rats, J Pharm Sci, 105, 2231, 10.1016/j.xphs.2016.04.025 Tatrai, 2019, A systematic in vitro investigation of the inhibitor preincubation effect on multiple classes of clinically relevant transporters, Drug Metab Dispos, 47, 768, 10.1124/dmd.118.085993 Ma, 2015, Time-dependent inhibition of hOAT1 and hOAT3 by anthraquinones, Biol Pharm Bull, 38, 992, 10.1248/bpb.b15-00217 Varma, 2014, Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model, J Pharmacol Exp Ther, 351, 214, 10.1124/jpet.114.215970